See more : GR Properties Limited (0108.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Edesa Biotech, Inc. (EDSA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Edesa Biotech, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Atlanticus Holdings Corporation (ATLCP) Income Statement Analysis – Financial Results
- Inception Growth Acquisition Limited (IGTA) Income Statement Analysis – Financial Results
- Tristar Acquisition I Corp. (TRIS-UN) Income Statement Analysis – Financial Results
- Eco Depot Inc. (ECDP) Income Statement Analysis – Financial Results
- MIC Electronics Limited (MIC.BO) Income Statement Analysis – Financial Results
Edesa Biotech, Inc. (EDSA)
About Edesa Biotech, Inc.
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 328.80K | 410.87K | 211.85K | 228.29K | 1.27M | 758.69K | 372.13K | 545.47K | 286.05K | 697.19K | 854.84K | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 183.47K | 118.19K | 118.79K | 17.60K | 101.29K | 445.32K | 534.45K | 1.13M | 840.25K | 760.26K | 576.53K | 436.40K | 1.01M | 386.09K | 0.00 | 0.00 |
| Gross Profit | 0.00 | -183.47K | -118.19K | -118.79K | 311.20K | 309.58K | -233.47K | -306.17K | 143.86K | -81.56K | -388.13K | -31.06K | -150.35K | -311.90K | 468.75K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 94.65% | 75.35% | -110.21% | -134.11% | 11.31% | -10.75% | -104.30% | -5.69% | -52.56% | -44.74% | 54.83% | 0.00% | 0.00% |
| Research & Development | 2.88M | 4.79M | 13.34M | 17.95M | 3.33M | 1.10M | 2.09M | 1.97M | 1.73M | 1.03M | 2.46M | 1.45M | 1.83M | 906.52K | 352.78K | 0.00 | 0.00 |
| General & Administrative | 4.13M | 4.43M | 5.04M | 5.73M | 3.38M | 2.05M | 2.76M | 2.94M | 3.32M | 3.23M | 2.87M | 2.24M | 4.43M | 5.84M | 1.15M | 78.50K | 0.00 |
| Selling & Marketing | 0.00 | -183.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.13M | 4.24M | 5.04M | 5.73M | 3.38M | 2.05M | 2.76M | 2.94M | 3.32M | 3.23M | 2.87M | 2.24M | 4.43M | 5.84M | 1.15M | 78.50K | 0.00 |
| Other Expenses | 0.00 | 0.00 | -780.26K | -10.34M | 37.41K | 0.00 | 0.00 | 0.00 | 24.63K | 0.00 | 0.00 | 0.00 | 112.14K | 87.33K | 30.37K | 0.00 | 0.00 |
| Operating Expenses | 7.01M | 9.22M | 17.59M | 13.34M | 6.71M | 3.14M | 4.84M | 4.92M | 5.05M | 4.26M | 5.33M | 3.65M | 6.37M | 6.83M | 1.53M | 78.50K | 0.00 |
| Cost & Expenses | 7.01M | 9.22M | 17.59M | 13.34M | 6.73M | 3.24M | 5.29M | 5.45M | 6.18M | 5.10M | 6.09M | 4.22M | 6.81M | 7.84M | 1.92M | 78.50K | 0.00 |
| Interest Income | 153.50K | 289.85K | 63.52 | 11.17K | 37.78K | 56.84K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.99K | 4.88K | 11.30K | 2.80K | 4.64K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.73K | 58.00 | 0.00 |
| Depreciation & Amortization | 186.05K | 183.47K | 118.19K | 118.79K | 57.56K | 6.37K | 188.37K | 179.32K | 149.57K | 159.52K | 158.31K | 124.83K | 112.14K | 87.33K | 13.27K | 4.70K | 0.00 |
| EBITDA | -6.13M | -8.19M | -17.43M | -13.22M | -6.35M | -2.83M | -4.85M | -4.85M | -4.87M | -2.65M | -8.25M | -3.72M | -6.43M | -3.51M | -761.82K | -64.65K | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,946.72% | -687.79% | -2,327.12% | -2,295.32% | -363.58% | -752.80% | -770.26% | 1,404.04% | -2,703.14% | -1,010.13% | -122.75% | 0.00% | 0.00% |
| Operating Income | -7.01M | -9.22M | -18.37M | -23.68M | -6.40M | -2.83M | -5.08M | -5.22M | -4.91M | -4.34M | -5.72M | -3.68M | -6.52M | -7.10M | -1.07M | -78.56K | 0.00 |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,946.72% | -689.30% | -2,397.11% | -2,288.59% | -385.97% | -571.85% | -1,536.69% | -674.37% | -2,280.23% | -1,018.37% | -124.63% | 0.00% | 0.00% |
| Total Other Income/Expenses | 845.50K | 849.14K | 822.67K | 10.34M | 37.41K | -309.45K | 40.10K | 194.70K | -110.52K | 1.53M | -2.78M | -11.21M | 1.37M | 3.50M | 477.02K | 4.64K | 0.00 |
| Income Before Tax | -6.17M | -8.37M | -17.55M | -13.34M | -6.36M | -2.78M | -5.04M | -5.03M | -5.02M | -2.81M | -8.41M | -14.89M | -5.20M | -7.09M | -588.37K | -73.92K | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,935.34% | -675.82% | -2,378.18% | -2,203.30% | -394.66% | -369.88% | -2,260.58% | -2,728.98% | -1,816.40% | -1,016.27% | -68.83% | 0.00% | 0.00% |
| Income Tax Expense | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | -55.40K | 800.00 | 800.00 | 7.20K | 36.80K | 27.20K | 800.00 | 800.00 | 800.00 | 1.60K | 0.00 | 0.00 |
| Net Income | -6.17M | -8.37M | -17.55M | -13.34M | -6.36M | -2.72M | -5.04M | -5.03M | -5.03M | -2.84M | -8.44M | -14.89M | -5.20M | -7.09M | -589.97K | -73.92K | 0.00 |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,935.59% | -662.33% | -2,378.56% | -2,203.65% | -395.23% | -374.73% | -2,267.88% | -2,729.12% | -1,816.68% | -1,016.39% | -69.02% | 0.00% | 0.00% |
| EPS | -1.93 | -2.93 | -8.37 | -7.74 | -5.18 | -4.15 | -10.54 | -218.72 | -23.92 | -15.01 | -46.75 | -121.14 | -49.86 | -78.14 | -15.88 | -7.67 | 0.00 |
| EPS Diluted | -1.93 | -2.93 | -8.37 | -7.73 | -5.18 | -4.15 | -10.54 | -211.28 | -23.92 | -15.01 | -46.75 | -121.14 | -49.86 | -78.14 | -15.88 | -7.67 | 0.00 |
| Weighted Avg Shares Out | 3.20M | 2.86M | 2.10M | 1.73M | 1.23M | 655.00K | 478.23K | 23.00K | 210.15K | 189.45K | 180.54K | 122.89K | 104.23K | 90.68K | 37.14K | 9.63K | 9.96K |
| Weighted Avg Shares Out (Dil) | 3.20M | 2.86M | 2.10M | 1.73M | 1.23M | 655.32K | 478.23K | 23.81K | 210.15K | 189.45K | 180.54K | 122.89K | 104.23K | 90.68K | 37.14K | 9.63K | 9.96K |
Edesa Biotech Shares Gain As Its COVID-19 Antibody Shows Favorable Mortality Reductions
Edesa Biotech Inc (NASDAQ: EDSA) has announced additional results from the Phase 2 part of an ongoing Phase 2/3 study of EB05 as a single-dose treatment for hospitalized COVID-19 patients. Related: Edesa Biotech Provides Update For COVID-19 Antibody Trial.
Why Edesa Biotech Shares Are Trading Higher Today
Edesa Biotech Inc (NASDAQ: EDSA) is trading higher Tuesday after the company announced additional results from the Phase 2 part of the ongoing Phase 2/3 study of EB05 in COVID-19. Edesa reported that EB05 demonstrated mortality reductions in multiple patient groups beyond...
Edesa Biotech Reports Favorable Mortality Reductions in COVID-19 Study
Mortality reductions demonstrated across multiple patient groups Additional efficacy signals recorded in a broad range of mild to severe ARDS patients Company to focus on critically ill population for Phase 3 TORONTO, ON / ACCESSWIRE / October 19, 2021 /...
Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients
On Sep 20, EDSA reports positive p2 data. On a request of the DSMB (Data and Safety Monitoring Board), p2 portion of EDSA's ongoing p2/3 trial was "preemptively unblinded".
EDSA Stock: The Covid-19 News Sending Edesa Biotech Soaring on Monday
Today, the announcement of positive clinical trial results has sent investors in Edesa Biotech and EDSA stock on a nice ride. The post EDSA Stock: The Covid-19 News Sending Edesa Biotech Soaring on Monday appeared first on InvestorPlace.
Why Edesa Biotech Shares Are Soaring Today
Edesa Biotech Inc (NASDAQ: EDSA) is surging higher Monday after the company announced positive Phase 2 data of its monoclonal antibody in hospitalized COVID-19 patients. Critically ill patients demonstrated a 68.5% reduction in the risk of dying when treated with EB05 over standard of care.
How To Play Edsa Biotech's Stock After 60% Surge
Edsa Biotech Inc. (NASDAQ:EDSA) shares are trading higher after the company announced Phase 2 Data of its Monoclonal Antibody in hospitalized COVID-19 patients. Critically ill patients demonstrated a 68.5% reduction in risk of dying when treated with EB05 over standard care.
EDSA Stock: Why It Significantly Increased Today
The stock price of Edesa Biotech Inc (NASDAQ: EDSA) increased by over 60% pre-market. This is why it happened.
Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients
Study unblinded due to strong efficacy signal for 28-day mortality endpoint Critically ill patients demonstrated a 68.5% reduction in the risk of dying when treated with EB05 over Standard of Care Data monitoring board recommends continuation to confirmatory Phase 3...
Edesa Biotech Provides Update For COVID-19 Antibody Trial
Edesa Biotech Inc (NASDAQ: EDSA) issued an update for the Phase 2/3 study evaluating its monoclonal antibody candidate, EB05, as single-dose therapy for hospitalized COVID-19 patients. Edesa reported that more than 525 subjects had been randomized into the study.
Source: https://incomestatements.info
Category: Stock Reports